Ironwood Pharmaceuticals IRWD
$4.70 −$0.01 (-0.21%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $4.60 -2.13%
Open$4.66
Prev close$4.71
Day range$4.65 – $4.87
Volume3.02M
Market cap$778.09M
P/E (TTM)5.2
Dividend yield–
IRWD Stock News
Headlines matching Ironwood Pharmaceuticals or the IRWD ticker, most recent first.
- Ironwood Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
- Ironwood Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director DENNER ALEXANDER J
- Ironwood Pharmaceuticals' Earnings Call Highlights LINZESS Surge Positive
- 10-Q: Ironwood Pharmaceuticals | 10-Q: Q2 2026 Earnings Report
- Ironwood Pharmaceuticals Q2 Adj. EPS $0.31 Misses $0.36 Estimate, Sales $113.041M Miss $114.844M Estimate Negative
- Ironwood Pharmaceuticals Reports Mixed Q2 Results; Raises FY26 Outlook Positive
- Ironwood Pharmaceuticals | SCHEDULE 13G/A: Others
- Craig-Hallum Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating
- Wells Fargo Maintains Ironwood Pharmaceuticals(IRWD.US) With Hold Rating, Maintains Target Price $5
- Analysts' Top Healthcare Picks: Ironwood Pharma (IRWD), Sionna Therapeutics, Inc. (SION)
- OneMedNet Collaborates With Inka Health To Provide Access To U.S. Real‐World Oncology Data Via IRWD Platform Powered By Palantir Foundry
- Ironwood Pharmaceuticals(IRWD.US) Director Sells US$20.53 Million in Common Stock
- Citizens JMP Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating, Raises Target Price to $10 Positive
- More Money In The Bank For Ironwood Pharmaceuticals Insiders Who Divested US$1.3m
- Ironwood Pharmaceuticals | 10-Q: Quarterly report
No comments yet — be the first to weigh in on IRWD.
Sign in to join the discussion.